Key result
Redo SAVR after prior TAVI carries ~14% in-hospital mortality and poor two-year survival.
Why the study?
Early- and mid-term outcomes following redo surgical aortic valve replacement in patients with previous transcatheter aortic valve implantation required analysis.
What are the early- and mid-term outcomes of redo surgical aortic valve replacement in patients with previous transcatheter aortic valve implantation?
Observational (n=28)
No
What are the early- and mid-term outcomes of redo surgical aortic valve replacement in patients with previous transcatheter aortic valve implantation?
Redo surgical aortic valve replacement after TAVI is feasible but carries significant in-hospital mortality (14.3%) and reduced mid-term survival, particularly when indicated for infective endocarditis.
Answers are grounded in this paper and cite their sources.
Provides early data on redo SAVR after TAVI failure; leaves open optimal valve selection and reintervention timing.
OBJECTIVES: The aim of this study was to analyse the early- and mid-term outcomes after redo surgical aortic valve replacement (SAVR) in patients with previous transcatheter aortic valve implantation (TAVI). METHODS: Retrospective single-centre analysis of early- and mid-term outcomes following redo SAVR in patients with previous TAVI between 2013 and 2020. Primary outcomes were in-hospital mortality and mid-term survival. RESULTS: During the study period, a total of 5756 patients underwent TAVI. Among them, 28 (0.5%) patients required redo SAVR after TAVI. During periods 2013-2016 and 2017-2020, 4/2184 (0.2%) patients and 24/3572 (0.7%) patients required SAVR after TAVI, respectively. The median logistic EuroSCORE was significantly higher at the time of SAVR than at the time of the index TAVI (5.9% vs 11.6%; P < 0.001). The median elapsed time between TAVI and redo SAVR was 7 months (3.5-14 months). Infective endocarditis (IE) was the most frequent indication for surgery [19 (67.8%) patients]. A total of 11 (39.3%) patients underwent isolated SAVR and 17 (60.7%) SAVR + additional cardiac surgical procedures. The overall in-hospital mortality was 14.3% (4/28). In-hospital mortality was 15.8% (3/19) among IE patients and 11.1% (1/9) among non-IE patients (P = 0.7). Overall estimated survival was 66.5%, 59.9% and 48.0% at 12, 18 and 24 months, respectively. Patients with IE showed a trend towards a lower estimated mid-term survival compared to non-IE patients [41.6% (95% confidence interval: 22.0-78.0%) vs 58.3% (95% confidence interval: 30.0-100%) survival at 24 months (P = 0.3)]. CONCLUSIONS: SAVR can be successfully performed in patients with prior TAVI despite the increased surgical risk and technical difficulty. IE is associated with decreased mid-term survival.
No takes yet. Share an insight, caveat, or question.
Marin‐Cuartas et al. (2022) conducted an observational in Previous transcatheter aortic valve implantation requiring redo surgical aortic valve replacement (n=28). Redo surgical aortic valve replacement (SAVR) was evaluated on in-hospital mortality and mid-term survival. Redo surgical aortic valve replacement in patients with prior TAVI had an overall in-hospital mortality of 14.3% and an estimated 24-month survival of 48.0%.
Synapse has enriched 10 related papers. Consider them for comparative context: